The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Hakimeh Ebrahimi-Nik et al.|Nature|2023Cited by 170
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng‐Ju Wu, Nabeel Bardeesy, Jason Eccleston et al.|Science|2024Cited by 87
Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Hakimeh Ebrahimi-Nik et al.|Cancer Research|2022Cited by 8
Supplementary table from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMeng‐Ju Wu, Nabeel Bardeesy, Lei Shi et al.|Unknown|2023Cited by 1
Supplementary Figure from Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMeng‐Ju Wu, Nabeel Bardeesy, Lei Shi et al.|Unknown|2023Cited by 1